Development and validation of a nomogram for predicting overall survival in small cell lung cancer: a multicenter analysis integrating multimodal therapy and molecular pathology [0.03%]
结合多模式治疗和分子病理学的多中心分析的小细胞肺癌预后列线图的制定与验证：预测总生存期
Zhihong Huang,Peng Mo,Naicheng Song et al.
Zhihong Huang et al.
Background: Small cell lung cancer (SCLC) is an aggressive malignancy with heterogeneous survival outcomes. Conventional staging systems do not fully capture the influence of multimodal treatment strategies or molecular p...
Lung cancer with EGFR PACC mutations: a practical review of available treatment options and novel therapies on the horizon [0.03%]
EGFR 21密码子PACC突变型肺癌的治疗选项及新疗法展望
Julia M Berg,Hollis Viray,Jenna Green et al.
Julia M Berg et al.
Epidermal growth factor receptor (EGFR)-P-loop and αC-helix compressing (PACC) mutations are a recently proposed structural-functional category of mutations that represent more than 10% of all EGFR mutations in non-small cell lung cancer (...
Real-world outcomes of consolidative durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer: the prognostic role of clinical frailty in the post-PACIFIC era [0.03%]
临床脆弱性在PACIFIC时代之后的巩固性度伐利尤单抗治疗III期非小细胞肺癌的真实世界结局及预后作用
Yoo-Kang Kwak,Ji Sang Kim,So Jung Lee et al.
Yoo-Kang Kwak et al.
Background: Consolidative durvalumab following concurrent chemoradiotherapy (CCRT) is the current standard of care for unresectable stage III non-small cell lung cancer (NSCLC). However, survival outcomes in real-world po...
Clinical practice review of systemic treatment in large cell neuroendocrine carcinoma [0.03%]
关于大细胞神经内分泌癌系统治疗的临床实践思考
Amanda S Cass,Isabella C Luckage,Albert G Linden et al.
Amanda S Cass et al.
Large cell neuroendocrine carcinomas (LCNECs) of the lung make up only 3.1% of all primary lung cancers, making them highly uncommon when compared to other primary lung cancers. For patients with stage I, II, or III LCNEC of the lung, surge...
Elevated baseline C-reactive protein predicts poorer survival in lung cancer: a 22-year retrospective cohort study [0.03%]
升高的基线C反应蛋白预测肺癌较差的生存率：一项22年的回顾性队列研究
Xiaomin Wei,Xiaoyan Liu,Mei Li et al.
Xiaomin Wei et al.
Background: Systemic inflammation has been implicated in cancer progression and C-reactive protein (CRP) is an established inflammatory biomarker. We investigated clinical and pathological factors associated with elevated...
Endostar combined with PD-1 blockade, radiotherapy, GM-CSF, and IL-2 (PRaG 2.0E) for refractory non-small cell lung cancer: a single-arm, phase II clinical trial (PRaG2.0E Study Protocol) [0.03%]
安罗替尼联合PD-1抑制剂、放疗、GM-CSF及IL-2（PRaG 2.0E方案）治疗难治性非小细胞肺癌的单臂Ⅱ期临床研究：研究方案
Shuaiyi Huang,Xiao Yang,Xiangrong Zhao et al.
Shuaiyi Huang et al.
Background: The lack of effective standard-of-care options for advanced refractory non-small cell lung cancer (NSCLC) represents an urgent unmet clinical need. PRaG 2.0, an optimized combination regimen comprising program...
Long-term survival and biomarkers of immunotherapy in small cell lung cancer: a systematic review [0.03%]
小细胞肺癌免疫疗法的长期生存和生物标志物系统评价
Sandra Laguna,Amaya Sádaba,Idoia Morilla et al.
Sandra Laguna et al.
Background: Metastatic small cell lung cancer (SCLC) is a fast-progressing malignancy with a dismal prognosis. For many decades platinum-based chemotherapy (CT) has been the standard treatment, and recent clinical trials ...
Utilizing clinical features, genetic mutations, and a 14-gene molecular assay for optimizing the management of multiple primary lung cancer [0.03%]
利用临床特征、遗传突变和一组14个基因的分子检测优化处理多原发性肺癌
Bowen Li,Zhibo Zheng,Zhina Wang et al.
Bowen Li et al.
Background: The increasing detection of multiple primary lung cancers (MPLCs) has outpaced the development of corresponding evidence-based management strategies. Current clinical practice remains constrained by two major ...
Applying artificial intelligence to ensure high quality and equitable lung cancer screening [0.03%]
利用人工智能确保高质量和公平的肺癌筛查
Jessica C Sieren,John D Newell Jr,Carmen E Guerra et al.
Jessica C Sieren et al.
Lung cancer screening (LCS) with low-dose computed tomography has the potential to improve early detection and promote more equitable health outcomes. However, traditional eligibility criteria, based primarily on age and smoking history, ma...
Distinct multiplex immunofluorescence-based immune and stromal marker expression profile of subcutaneously metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report [0.03%]
SMARCA4缺陷性未分化胸部肿瘤皮下转移的多重免疫荧光标志物表达谱：1例报告
Hongmin Li,Ying Liang,Yufei Wang et al.
Hongmin Li et al.
Background: The SMARCA4 gene encodes the BRG1 protein, a key component of the switch (SWI)/sucrose nonfermenting (SNF) chromatin remodeling complex, and its loss has been implicated in the pathogenesis of various tumors. ...